Lilly stock soars to all-time high on strong sales, led by Mounjaro
Much of the excitement is due to strong results from Mounjaro, which hit the market in June 2022 as a treatment for Type 2 diabetes and rang up $979.7 million in the quarter.
Pharmaceutical
Articles
Lilly reports surging profit, raises full-year guidance
The Indianapolis-based pharmaceutical company’s first-quarter performance was driven by strong sales of leading drugs for diabetes, cancer and other diseases.
IU Health’s new pharmacy hub aims to cut costs
Indiana University Health’s 70,000-square-foot pharmacy hub and distribution center in Plainfield has enough pills, lotions, and infusible and injectable drugs under one roof to supply its 16 hospitals and hundreds of clinics for weeks.
Tornado damage to Pfizer plant likely to cause long-term drug shortages
The fallout from a Pfizer factory being damaged by a tornado could put even more pressure on already-strained drug supplies at U.S. hospitals, experts say.
New research shows Lilly drug slows decline in Alzheimer’s patients
If U.S. regulators approve, the drug would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease—after rival Leqembi. Both drugs pose a serious safety concern—brain swelling and bleeding.
Alzheimer’s caregivers watching closely as drugs finally hit market
More than 110,000 Hoosiers suffer from Alzheimer’s disease, which robs people of their memories and abilities to do daily tasks, and is the nation’s sixth-leading cause of death.
Lilly to spend up to $1.93 billion to acquire Boston biopharmaceutical firm
With the acquisition of Versanis Bio, Lilly is adding another promising treatment to its weight-loss drug pipeline.
First over-the-counter birth control pill gets FDA approval
Women’s health advocates hope the decision will pave the way for more over-the-counter birth control options.
IBJ Podcast: Lilly in middle of big battle over future of drug prices for seniors
In this week’s edition of the IBJ Podcast, reporter John Russell discusses Medicare’s new power to negotiate drug prices and its effects on patients, drug makers and the rest the health care industry. Eli Lilly and Co. would like to see some changes.
Drugmakers warn new law will deter discoveries
David Ricks, CEO of Indianapolis-based drugmaker Eli Lilly and Co., is turning up the volume on his concerns over a new law that would allow Medicare, for the first time, to negotiate drug prices.
Next step for obesity drug makers replacing needles with pills
Medical experts predict the pills will be popular, especially among people who want to lose weight but are fearful of needles.
Contract drugmaker Catalent shrinks as pandemic wanes
The New Jersey-based company has announced two large rounds of layoffs at its Bloomington plant within six months—400 workers last December and 150 this month.
Inflation Reduction Act foes race to repeal climate, drug pricing programs
A growing roster of corporate and political foes has started to lay siege to the law, hoping to erode some of its key provisions before they can take effect.
Indiana to receive $19M in opioid settlement funds this year
This year is the second year Indiana has received money from a national settlement with opioid distributors and manufacturers for opioid-related harms.
Insurers clamping down on doctors who prescribe Ozempic for weight loss
Indianapolis-based Elevance Health, which operates Anthem plans, said that in most cases, it won’t cover Ozempic unless a patient is diagnosed with diabetes and has tried another medication to manage it, but physicians can still prescribe it.
Lilly battling rivals for breast-cancer patients
The Indianapolis-based pharmaceutical giant is spending hundreds of millions of dollars to win over patients with an extensive advertising campaign.
Medicare to expand coverage for new class of costly Alzheimer’s drugs
Groups such as the Alzheimer’s Association have pushed Medicare to cover the new Alzheimer’s drugs—including those cleared on an expedited basis—saying that the FDA should be the final arbiter of safety and efficacy of drugs.
Eli Lilly settles class-action insulin lawsuit for $13.5M
Under the agreement, Lilly has agreed to continue its cap on out-of-pocket costs for its users at $35 a month for four years.
SpectronRx teams with Belgian research center to make cancer therapies in Europe
The Indianapolis-based radiopharmaceutical company said it plans to help open a facility in Belgium to make therapeutic agents for cancer patients.
Can new Indiana law lower drug costs? Answer is as clear as mud
Senate Enrolled Act 8 is part of a sweeping effort this year by the Indiana General Assembly to bring down the cost of health care across the state, where prices are among the highest in the country.